Cure8 news brief
Patients and clinicians may care because the investigational drug duvakitug reportedly sustained clinical and endoscopic benefits through 44 weeks in both ulcerative colitis and Crohn’s disease, which could represent a potential future treatment option if later trials and regulatory review confirm efficacy and safety.
The announcement is early-stage (phase 2b extension) and does not mean the drug is approved.
Adult patients with moderate-to-severe ulcerative colitis or Crohn’s disease, clinicians who treat IBD, and researchers following emerging drug development in IBD.
Teva and Sanofi reported long-term (44-week) extension results from the phase 2b RELIEVE UCCD program showing that the investigational oral agent duvakitug maintained clinical and endoscopic improvements in patients with moderately-to-severely active ulcerative colitis and Crohn’s disease.
The announcement emphasizes maintained rates of clinical remission/response and endoscopic improvement/response at week 44 versus earlier timepoints and notes the drug remains investigational and not evaluated by regulators.
This is a company press-type release summary of extension-phase data rather than a peer-reviewed paper; it describes maintained efficacy in both UC and CD populations over 44 weeks but provides no detailed methods, numerical results, safety data, or independent review. It does not replace clinical guidance or regulatory assessment.
If you’re tracking emerging IBD therapies, this news indicates ongoing development of duvakitug and continued collaboration between Sanofi and Teva across IBD and related indications. Expect more detailed data to appear in scientific presentations or full study reports for clinicians and researchers to evaluate benefit-risk.
This item is a company press-style news report summarizing phase 2b long-term extension results; it lacks detailed numeric outcomes, safety results, and independent peer review. Duvakitug remains investigational and has not been evaluated or approved by regulators.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
New phase IIb trial results suggest an anti‑TL1A antibody (duvakitug) produced measurable benefit in both Crohn’s disease and ulcerative colitis, which could lead to a new treatment option if later phase III trials...
A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...
